Tubing is arguably one of the earliest components in the pharmaceutical industry to be associated with single-use technology (SUT). Long before broad proliferation of SUT, pharmaceutical companies were using silicone, PVC, and early-generation thermoplastic elastomer (TPE) tubing materials to connect traditional infrastructure. However, while advancements in other single-use systems and components, such as bioreactors, have been heralded, innovation in single-use tubing has been far less pronounced.
We work in an industry that has an immediate impact on the welfare of people. Every component used in biopharmaceutical processing — large or small — is pivotal to the ultimate goal of delivering safe and effective medication. Advancements associated with tubing may not necessarily be perceived as revolutionary, but there is an ability to innovate in this space, which based on the above assertion represents necessary progress.
To deliver cleaner materials and actively mitigate risk in biopharmaceutical manufacturing, evaluation of single-use tubing based on the following development principles should take place.